[1] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
|
[2] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918.
|
[3] |
FAN PL, XIA HS, DING H, et al. Characterization of early hepatocellular carcinoma and high-grade dysplastic nodules on contrast-enhanced ultrasound: Correlation with histopathologic findings[J]. J Ultrasound Med, 2020, 39( 9): 1799- 1808. DOI: 10.1002/jum.15288.
|
[4] |
CHEN YL, LU Q, ZHU YL, et al. Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on pre-operative clinical data and contrast-enhanced ultrasound characteristics[J]. Ultrasound Med Biol, 2022, 48( 7): 1190- 1201. DOI: 10.1016/j.ultrasmedbio.2022.02.014.
|
[5] |
DING WZ, WANG Z, LIU FY, et al. A hybrid machine learning model based on semantic information can optimize treatment decision for Naïve single 3-5-cm HCC patients[J]. Liver Cancer, 2022, 11( 3): 256- 267. DOI: 10.1159/000522123.
|
[6] |
HUANG P, NI XY, ZHOU CW, et al. Subcentimeter nodules with diagnostic hallmarks of hepatocellular carcinoma: Comparison of pathological features and survival outcomes with nodules measuring 1-2 cm[J]. J Hepatocell Carcinoma, 2023, 10: 169- 180. DOI: 10.2147/JHC.S401027.
|
[7] |
GUO W, SUN YF, SHEN MN, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma[J]. Clin Cancer Res, 2018, 24( 9): 2203- 2213. DOI: 10.1158/1078-0432.CCR-17-1753.
|
[8] |
QU CF, WANG YT, WANG P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116( 13): 6308- 6312. DOI: 10.1073/pnas.1819799116.
|
[9] |
HUANG YH, ZHANG CZ, HUANG QS, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma[J]. J Hepatol, 2021, 74( 4): 838- 849. DOI: 10.1016/j.jhep.2020.10.037.
|
[10] |
Expert Committee for Writing the Expert Consensus on Pathological Diagnosis of Intrahepatic cholangiocarcinoma( 2022 version). Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma(2022 version)[J]. Chin J Pathol, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423.
《肝内胆管癌病理诊断专家共识(2022版)》编写专家委员会. 肝内胆管癌病理诊断专家共识(2022版)[J]. 中华病理学杂志, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423.
|
[11] |
WANG H, CHEN JJ, YIN SY, et al. A grading system of microvascular invasion for patients with hepatocellular carcinoma undergoing liver resection with curative intent: A multicenter study[J]. J Hepatocell Carcinoma, 2024, 11: 191- 206. DOI: 10.2147/JHC.S447731.
|
[12] |
MIRDAD RS, MADISON HYER J, DIAZ A, et al. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough?[J]. J Surg Oncol, 2021, 123( 7): 1568- 1577. DOI: 10.1002/jso.26433.
|
[13] |
XIA Y, LI J, LIU GH, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: A randomized clinical trial[J]. JAMA Oncol, 2020, 6( 2): 255- 263. DOI: 10.1001/jamaoncol.2019.4477.
|
[14] |
XU XL, LIU XD, LIANG M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: Systematic review of randomized controlled trials with meta-analysis and trial sequential analysis[J]. Radiology, 2018, 287( 2): 461- 472. DOI: 10.1148/radiol.2017162756.
|
[15] |
YANG PH, SI AF, YANG J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165( 4): 721- 730. DOI: 10.1016/j.surg.2018.09.016.
|
[16] |
WANG Q, LI HJ, DAI XM, et al. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies[J]. Int J Surg, 2022, 105: 106821. DOI: 10.1016/j.ijsu.2022.106821.
|
[17] |
QIN SK, CHEN MS, CHENG AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma(IMbrave050): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402( 10415): 1835- 1847. DOI: 10.1016/S0140-6736(23)01796-8.
|
[18] |
ZHANG YJ, CHEN MS, CHEN Y, et al. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma[J]. JAMA Netw Open, 2021, 4( 9): e2126992. DOI: 10.1001/jamanetworkopen.2021.26992.
|
[19] |
LYU N, WANG X, LI JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial(FOHAIC-1)[J]. J Clin Oncol, 2022, 40( 5): 468- 480. DOI: 10.1200/JCO.21.01963.
|
[20] |
HE MK, LI QJ, ZOU RH, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5( 7): 953- 960. DOI: 10.1001/jamaoncol.2019.0250.
|
[21] |
CHAN AWH, ZHONG JH, BERHANE S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection[J]. J Hepatol, 2018, 69( 6): 1284- 1293. DOI: 10.1016/j.jhep.2018.08.027.
|
[22] |
PENG ZW, FAN WZ, ZHU BW, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial(LAUNCH)[J]. J Clin Oncol, 2023, 41( 1): 117- 127. DOI: 10.1200/JCO.22.00392.
|
[23] |
SU K, GU T, XU K, et al. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score matching study[J]. Hepatol Int, 2022, 16( 4): 858- 867. DOI: 10.1007/s12072-022-10339-2.
|
[24] |
QIN SK, CHAN SL, GU SZ, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): A randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402( 10408): 1133- 1146. DOI: 10.1016/S0140-6736(23)00961-3.
|
[1] | Yuxiang GUO, Maosen WANG, Zhongyuan LIU, Xudong ZHANG, Pengfei MA, Xiangkun WANG, Renfeng LI. Advances in the diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus[J]. Journal of Clinical Hepatology, 2025, 41(2): 359-364. doi: 10.12449/JCH250224 |
[2] | Jiarui YANG, Jianxin JIANG. An excerpt of EASL clinical practice guidelines on the management of hepatocellular carcinoma(2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(2): 234-239. doi: 10.12449/JCH250207 |
[3] | Xinyu BI, Jianqiang CAI. The therapeutic paradigm of liver surgery in the era of conversion therapy[J]. Journal of Clinical Hepatology, 2024, 40(9): 1721-1724. doi: 10.12449/JCH240901 |
[4] | National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer (2024 edition)[J]. Journal of Clinical Hepatology, 2024, 40(5): 893-918. doi: 10.12449/JCH240508 |
[5] | Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2024, 40(5): 919-927. doi: 10.12449/JCH240509 |
[6] | Jiahao XU, Dongxu YIN, Yuchen LI, Fujie CHEN, Mingda WANG, Tian YANG. Systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2306-2314. doi: 10.12449/JCH241127 |
[7] | Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma: Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027 |
[8] | Zhiwen LIN, Hongzhi LIU, Yongyi ZENG, Kecan LIN. Hotspots and advances in neoadjuvant therapy for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(9): 2031-2038. doi: 10.3969/j.issn.1001-5256.2023.09.002 |
[9] | Ruilin FAN, Zongren DING, Yongyi ZENG. Precise diagnosis and treatment of biliary tract carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(9): 2025-2030. doi: 10.3969/j.issn.1001-5256.2023.09.001 |
[10] | Rui ZHANG, Zhimin GENG. Systemic therapy for gallbladder cancer in the era of precision medicine: Coexistence of opportunities and challenges[J]. Journal of Clinical Hepatology, 2023, 39(9): 2049-2056. doi: 10.3969/j.issn.1001-5256.2023.09.005 |
[11] | Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037 |
[12] | Zhu GuiQi, Tang Zheng, Shi YingHong, Fan Jia. Research advances in systemic therapy for hepatocellular carcinoma in the era of precision medicine[J]. Journal of Clinical Hepatology, 2020, 36(10): 2173-2178. doi: 10.3969/j.issn.1001-5256.2020.10.003 |
[13] | Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042 |
[14] | Liang TingBo. Current status and perspectives of neoadjuvant therapy for pancreatic cancer[J]. Journal of Clinical Hepatology, 2019, 35(5): 946-952. doi: 10.3969/j.issn.1001-5256.2019.05.003 |
[15] | Zhu Bing, Xin ShaoJie, You ShaoLi. Precision medicine and treatment strategies for liver failure[J]. Journal of Clinical Hepatology, 2018, 34(9): 1832-1835. doi: 10.3969/j.issn.1001-5256.2018.09.003 |
[16] | Li Zhao, Zhu JiYe. An interpretation of diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. Journal of Clinical Hepatology, 2017, 33(9): 1655-1657. doi: 10.3969/j.issn.1001-5256.2017.09.006 |
[17] | National Health and Family Planning Commission of the People’s Republic of China;. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. Journal of Clinical Hepatology, 2017, 33(8): 1419-1431. doi: 10.3969/j.issn.1001-5256.2017.08.003 |
[18] | Qi Bing, Shang Dong. ACR appropriateness criteria resectable pancreatic cancer[J]. Journal of Clinical Hepatology, 2017, 33(7): 1249-1254. doi: 10.3969/j.issn.1001-5256.2017.07.008 |
[19] | Liu Chang, Yang YinMo. Emphasis on neoadjuvant therapy for “resectable”pancreatic cancer[J]. Journal of Clinical Hepatology, 2015, 31(5): 645-648. doi: 10.3969/j.issn.1001-5256.2015.05.001 |
[20] | Ministry of Health of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2011)[J]. Journal of Clinical Hepatology, 2011, 27(11): 1141-1159. |